Business
Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting
CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that data from its novel cell therapy platform will be shared in an oral presentation at the 67th ASH Annual Meeting, being held December 6-9, 2025 in Orlando, FL. “Being selected to give an oral presentation at ASH is a tremendous honor and a major milestone,” said Sanjeev Luther
About this update from Ernexa Therapeutics Inc.
[{"type":"image","alt":"Ernexa Therapeutics Inc.","displaySize":"","headline":null,"caption":"Ernexa Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":166,"url":"https://media.zenfs.com/en/globenewswire.com/5060d0692cdc61118022bf7e5069f69d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_oDYUSflXSfeQ8zZ8t_rmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5060d0692cdc61118022bf7e5069f69d","width":300,"height":166}},"lazy":false},{"type":"text","content":"CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that data from its novel cell therapy platform will be shared in an oral presentation at the 67th ASH Annual Meeting, being held December 6-9, 2025 in Orlando, FL.","length":382,"tagName":"p"},{"type":"text","content":"“Being selected to give an oral presentation at ASH is a tremendous honor and a major milestone,” said Sanjeev Luther, President & CEO of Ernexa Therapeutics. “It’s a recognition of the potential of our iMSC platform to transform the tumor microenvironment and drive a targeted immune response. We’re proud to share this work and move closer to delivering innovative therapies for patients facing ovarian cancer and other hard-to-treat diseases.”","length":450,"tagName":"p"},{"type":"text","content":"Details of the oral presentation are as follows:","length":48,"tagName":"p"},{"type":"text","content":"Title: Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct Pro-inflammatory TMEsAbstract Number: abs25-15026Presenter: Michael Andreeff, MD, PhD, Professor of Medicine, Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer CenterSession: 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Cellular Immunotherapy Beyond CAR-T: Emerging Platforms and StrategiesPresentation Date and Time: December 6, 2025 from 3:00 PM - 3:15 PM ESTLocation: OCCC - Chapin Theater (320)","length":595,"tagName":"p"},{"type":"text","content":"The data being presented reflects preclinical findings supporting ERNA-101, Ernexa’s lead therapy candidate for ovarian cancer. This oral...